再発した急性骨髄性白血病(AML)の小児におけるベネトクラクス
再発した AML の小児におけるベネトクラクスの有無にかかわらず、フルダラビン/シタラビン/ゲムツズマブ オゾガマイシンの無作為化第 3 相試験
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
調査の概要
状態
条件
詳細な説明
Relapse of AML is driven by chemotherapy resistant stem cells. One mechanism of chemotherapeutic resistance in AML is the overexpression of the protein B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein which sequesters intracellular activators of apoptosis. Venetoclax is a selective, potent, orally bioavailable, small molecule inhibitor of BCL-2 that restores programmed cell death in cancer cells.
This is a trial for children, adolescents and young adults with 2nd relapsed AML or 1st relapsed AML unable to receive additional anthracycline.
This is randomized trial of venetoclax in combination with intensive chemotherapy (fludarabine/cytarabine/gemtuzumab ozogamicin) for the first two cycles (42-day-cycles) that would inform and evaluate if this agent is an effective option for this population to improve its poor prognosis. Participants can receive up to two cycles of induction chemotherapy before hematopoietic stem cell transplantation (HSCT). If participants who have perceived clinical benefit cannot be transplanted after the 2 cycles, maintenance treatment may be given at the discretion of the investigator. In Arm B (experimental arm), participants can continue venetoclax if they have perceived clinical benefit, and maintenance therapy will combine venetoclax with azacitidine for a maximum of 24 cycles. In Arm A (control arm), participants will receive azacitidine in monotherapy. Maintenance is continued until clinical progression or unacceptable toxicity with a maximum of 24 cycles.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85016
- Phoenix Children's Hospital
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72202
- Arkansas Children's Hospital
-
-
California
-
Long Beach、California、アメリカ、90806
- MemorialCare Miller Children's and Women's Hospital Long Beach
-
Orange、California、アメリカ、92868
- Children's Hospital of Orange County Main Campus - Orange
-
San Francisco、California、アメリカ、94158
- Benioff Children's Hospital - Mission Bay
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Children's Hospital Colorado
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- Yale University
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19803
- Nemours Alfred I. Dupont Hospital for Children
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children's National - Main Hospital
-
-
Florida
-
Fort Myers、Florida、アメリカ、33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville、Florida、アメリカ、32610
- University of Florida Health Shands Children's Hospital
-
Jacksonville、Florida、アメリカ、32207
- Nemours Children's Specialty Care Jacksonville
-
Orlando、Florida、アメリカ、32827
- Nemours Children's Hospital - Orlando
-
Tampa、Florida、アメリカ、33607
- Saint Joseph's Hospital - Tampa
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Children's Healthcare of Atlanta
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96826
- Kapi'olani Medical Center for Women and Children
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Chicago、Illinois、アメリカ、60637
- Comer Children's Hospital
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University School of Medicine
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Stead Family Children's Hospital
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- Norton Children's Hospital
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109-4259
- C.S. Mott Children's Hospital
-
Detroit、Michigan、アメリカ、48201
- Children's Hospital of Michigan
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- Masonic Cancer Center
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- The Children's Mercy Hospital - Adele Hall Campus
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine in St. Louis
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89135
- Alliance for Childhood Diseases dba Cure 4 The Kids Foundation
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center, HMH
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Irving Medical Center
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center - New York
-
Queens、New York、アメリカ、11040
- Cohen Children's Medical Center
-
-
Ohio
-
Columbus、Ohio、アメリカ、43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Doernbecher Children's Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
-
South Carolina
-
Columbia、South Carolina、アメリカ、29203
- Prisma Health Richland Hospital
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105-3678
- St. Jude Children's Research Hospital
-
Nashville、Tennessee、アメリカ、37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- Harold C. Simmons Comprehensive Cancer Center
-
Houston、Texas、アメリカ、77030
- Texas Children's Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113
- Primary Children's Hospital
-
-
Virginia
-
Richmond、Virginia、アメリカ、23219
- Children's Hospital of Richmond at Virginia Commonwealth University
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
-
-
-
Central District
-
Petach Tikvah、Central District、イスラエル、4920235
- Schneider Children's Medical Center of Israel
-
-
-
-
Genoa
-
Genova、Genoa、イタリア、16147
- Istituto Giannina Gaslini
-
-
Monza and Brianza
-
Monza、Monza and Brianza、イタリア、20900
- Fondazione IRCCS San Gerardo dei Tintori
-
-
Rome
-
Roma、Rome、イタリア、00165
- Ospedale Pediatrico Bambino Gesù
-
-
Turin
-
Torino、Turin、イタリア、10126
- Ospedale Infantile Regina Margherita
-
-
-
-
-
Utrecht、オランダ、3584 CS
- Prinses Maxima Centrum Kinderoncologie
-
-
-
-
Queensland
-
South Brisbane、Queensland、オーストラリア、4101
- Children's Health Queensland Hospital and Health Service
-
-
Victoria
-
Parkville、Victoria、オーストラリア、3052
- The Royal Children's Hospital - Children's Cancer Centre
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア、6009
- Perth Children's Hospital
-
-
-
-
-
Vienna、オーストリア、1090
- Sankt Anna-Kinderspital
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T3B 6A8
- Alberta Children's Hospital
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6H 3N1
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3K 6R8
- Izaak Walton Killam (IWK) Health Center
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- SickKids - The Hospital for Sick Children
-
-
-
-
-
Zurich、スイス、8032
- Universitaets - Kinderspital Zürich
-
-
-
-
Stockholm County
-
Stockholm、Stockholm County、スウェーデン、171 76
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
Barcelona、スペイン、08950
- Hospital Sant Joan de Déu Barcelona
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebrón
-
Madrid、スペイン、28009
- Hospital Infantil Universitario Niño Jesús
-
Valencia、スペイン、46026
- Hospital Universitario La Fe
-
-
-
-
Prague
-
Prague、Prague、チェコ、150 06
- Fakultni nemocnice v Motole
-
-
-
-
Capital Region
-
Copenhagen、Capital Region、デンマーク、2100
- Rigshospitalet
-
-
-
-
-
Augsburg、ドイツ、86156
- Universitätsklinikum Augsburg
-
Berlin、ドイツ、13353
- Charité - Universitätsmedizin Berlin
-
Frankfurt、ドイツ、60590
- Universitätsklinikum Frankfurt
-
Münster、ドイツ、48149
- Padiatrische Hamatologie und Onkologie
-
Münster、ドイツ、49149
- Universitätsklinikum Münster
-
-
-
-
Auckland
-
Grafton、Auckland、ニュージーランド、1023
- Starship Children's Hospital
-
-
-
-
-
Oslo、ノルウェー、0372
- Oslo Universitetssykehus
-
-
-
-
Etelä-Suomen Lääni
-
Helsinki、Etelä-Suomen Lääni、フィンランド、FI-00290
- Uusi Lastensairaala
-
-
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、フランス、31059
- CHU de Toulouse - Hôpital des Enfants
-
-
Hauts-de-France
-
Loos、Hauts-de-France、フランス、59120
- Hôpital Jeanne de Flandre
-
-
Loire-Atlantique
-
Nantes、Loire-Atlantique、フランス、44093
- CHU de Nantes - Hôpital Femme-Enfant-Adolescent
-
-
Rhône
-
Lyon、Rhône、フランス、69008
- Institut d'Hématologie et d'Oncologie Pédiatrique
-
-
Île-de-France Region
-
Paris、Île-de-France Region、フランス、75012
- Hôpital Armand-Trousseau
-
Paris、Île-de-France Region、フランス、75019
- Hôpital Universitaire Robert-Debré
-
-
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、ベルギー、9000
- Universitair Ziekenhuis Gent
-
-
-
-
Lisbon District
-
Lisbon、Lisbon District、ポルトガル、1099-023
- Instituto Portugues De Oncologia De Lisboa Francisco Gentil
-
-
-
-
-
Osaka、日本、534-0021
- Osaka City General Hospital
-
-
Aiti
-
Nagoya、Aiti、日本、453-8511
- Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital
-
-
Hyōgo
-
Kobe、Hyōgo、日本、650-0047
- Hyogo Prefectural Kobe Children's Hospital
-
-
Saitama
-
Saitama-Shi、Saitama、日本、330-8777
- Saitama Prefectural Children's Medical Center
-
-
Tokyo
-
Setagaya-Ku、Tokyo、日本、157-8535
- National Center for Child Health and Development
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
-
Participants must have enrolled on APAL2020SC, NCT Number: NCT04726241 prior to enrollment on ITCC-101/APAL2020D. (This is only applicable for participants in USA/Canada/Australia/New Zealand sites/Blood Cancer United territory).
-
Participants must be >28 days of age and < 22 years of age at enrollment.
-
Participants must have one of the following:
-
Children, adolescents, and young adults with AML without demonstrated FLT3/internal tandem duplication (ITD) mutation. Ideally, the status of the mutation needs to be proven in the current relapse. Nevertheless, patients with previous FLT3/ITD negative test from prior lines can be included based on local results in order to not delay the start of treatment.
-
And participants must have AML which is either:
- Untreated second relapse, in participants who are sufficiently fit to undergo another round of intensive chemotherapy, or
- Untreated first relapse, in participants who cannot tolerate additional anthracycline containing chemotherapy per investigator discretion.
-
-
Participants must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2 (≥ 50% Lansky or Karnofsky score).
-
Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to start of protocol treatment:
-
Cytotoxic chemotherapy: Must not have received cytotoxic chemotherapy within 14 days prior to start of protocol treatment, except for corticosteroids, low dose cytarabine or hydroxyurea that can be given up to 24 hours prior to start of protocol treatment.
-
Intrathecal cytotoxic therapy: No wash-out time is required for participants having received any combination of intrathecal cytarabine, methotrexate, and/or hydrocortisone.
-
Antibodies: ≥ 21 days must have elapsed from infusion of last dose of an antibody-drug conjugate before start of protocol treatment. For unmodified antibodies or T cell engaging antibodies, 2 half-lives must have elapsed before start of protocol treatment. Any toxicity related to prior antibody therapy must be recovered to Grade ≤ 1.
-
Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors): ≥ 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors) before start of protocol treatment.
-
Hematopoietic growth factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or ≥7 days for short-acting growth factor before start of protocol treatment.
-
Radiation therapy (RT) (before start of protocol treatment):
- ≥ 14 days have elapsed for local palliative RT (small port);
- ≥ 84 days must have elapsed if prior craniospinal RT or if ≥ 50% radiation of pelvis;
- ≥ 42 days must have elapsed if other substantial bone marrow (BM) radiation.
-
Stem Cell Infusions (before start of protocol treatment):
- ≥ 84 days since allogeneic (non-autologous) bone marrow or stem cell transplant (with or without total body irradiation [TBI]) or boost infusion (any stem cell product; not including donor lymphocyte infusion [DLI]);
- No evidence of active graft versus host disease (GVHD).
-
Participants who are receiving cyclosporine, tacrolimus or other agents to treat or prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial. Participants must be off medications to treat or prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant for at least 14 days prior to enrollment.
-
Cellular Therapy: ≥ 42 days after the completion of donor lymphocyte infusion (DLI) or any type of cellular therapy (e.g., modified T cells, natural killer [NK] cells, dendritic cells, etc.) before start of protocol treatment.
-
Participants with prior exposure to venetoclax are eligible in this trial.
-
-
Adequate organ function:
-
Adequate Renal Function defined as:
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60ml/min/1.73 m^2, or
- Normal serum creatinine based on age/sex
-
Adequate Liver Function defined as:
- Direct bilirubin < 1.5 x upper limit of normal (ULN), and
- Alkaline phosphatase ≤ 2.5 x ULN, and
- Serum glutamic pyruvic transaminase (SGPT) alanine aminotransferase (ALT) ≤ 2.5 x ULN. If higher transaminases outside these ranges (up to 5x ULN) are due to a radiographically identifiable leukemia infiltrate, the participant will remain eligible. Transaminase elevation up to 5x ULN is also allowed in case of steatosis on echography.
-
Cardiac performance: Minimum cardiac function defined as:
- No history of congestive heart failure in need of medical treatment
- No pre-treatment diminished left ventricular function on echocardiography (shortening fraction [SF] < 25% or ejection fraction [EF] < 40%)
- No signs of congestive heart failure at presentation of relapse.
-
-
Participant, parent or guardian must sign and date informed consent and pediatric assent (when required), prior to the initiation of screening or study specific procedures, according to local law and legislation.
Exclusion Criteria
-
Participants who in the opinion of the investigator may not be able to comply with the study requirements of the study, are not eligible.
-
Participants with Down syndrome.
-
Participants with Acute promyelocytic leukemia (APL) or Juvenile myelomonocytic leukemia (JMML).
-
Participants with isolated CNS3 disease or symptomatic CNS3 disease.
-
Participants with malabsorption syndrome or any other condition that precludes enteral administration of venetoclax.
-
Participants who are currently receiving an investigational drug other than those specified for this study.
-
Participants with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known congenital bone marrow failure syndrome.
-
Participants with known prior allergy to any of the medications used in protocol therapy.
-
Participants with documented active, uncontrolled infection at the time of study entry.
-
Known hepatitis C virus (HCV), hepatitis B virus (HBV) (known positive hepatitis B virus (HBV) surface antigen (HBsAg) results), or human immunodeficiency virus (HIV) infection.
-
Concomitant Medications
- Participants who have received strong and moderate CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort within 7 days of the start of study treatment.
- Participants who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days of the start of study treatment.
- Participants who have hypersensitivity to the active substance or to any of the excipients listed in summary of product characteristics (SPC).
-
Pregnancy or Breast-Feeding:
- Participants who are pregnant or breast-feeding.
- Participants of reproductive potential may not participate unless they have agreed to use a highly effective contraceptive method per Clinical Trial Facilitation Group (CTFG) guidelines for the duration of study therapy and at least 30 days after last dose of venetoclax, or 7 months after gemtuzumab ozogamicin treatment, or for 6 months after the completion of all study therapy, whichever is longer.
- Male participants must use a condom during intercourse and agree not to father a child or donate sperm during therapy and for the duration of study therapy and at least 30 days after last dose of venetoclax or 4 months after last dose of gemtuzumab ozogamicin, 6 months from the last dose of cytarabine, or 90-days after last exposure to any other chemotherapy, whichever is longer.
Additional criteria to receive a gemtuzumab ozogamicin infusion:
Gemtuzumab ozogamicin should not be given:
- to participants with history of veno-occlusive disease (VOD)/Sinusoidal obstruction syndrome (SOS) grade 3 or 4
- to participants with CD33 negative leukemic blasts (determined at local lab)
Note that these participants are eligible for the study but will not be treated with gemtuzumab ozogamicin.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm A: Control Arm without Venetoclax
During Cycle 1 (42-day-cycles), participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5. Gemtuzumab 3 mg/m^2 will be given on Day 6 (only for participants with CD33 expression on leukemia blasts). During Cycle 2 participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5. After Cycle 2 participants are assessed for HSCT or azacitidine maintenance therapy. |
Intravenous (IV) infusion Intravenous (IV) infusion Intravenous (IV) infusion Intravenous (IV) infusion or subcutaneous injection |
|
実験的:Arm B: Experimental Arm with Venetoclax
During Cycle 1 (42-day-cycles), participants will receive 300 mg adult dose equivalent of venetoclax once on Day 1 followed by 600 mg adult dose equivalent of venetoclax on Days 2-21. Participants will also receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 8-12. Gemtuzumab 3 mg/m^2 will be given on Day 13 (only for participants with CD33 expression on leukemia blasts). During Cycle 2, participants will receive 600 mg adult dose equivalent of venetoclax on Days 1-21. Participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5. After Cycle 2 participants are assessed for HSCT or azacitidine maintenance therapy in combination with venetoclax. |
Intravenous (IV) infusion Intravenous (IV) infusion Intravenous (IV) infusion Intravenous (IV) infusion or subcutaneous injection Orally via tablet or powder suspension |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
全生存期間 (OS)
時間枠:5年まで
|
5年まで
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
形態 イベント フリー サバイバル (EFS)
時間枠:5年まで
|
5年まで
|
|
フローベースのイベント フリー サバイバル (EFS)
時間枠:5年まで
|
5年まで
|
|
形態学的全奏効率 (ORR)
時間枠:84日目まで
|
84日目まで
|
|
フローベースの全奏効率 (ORR)
時間枠:84日目まで
|
84日目まで
|
|
応答期間 (DOR)
時間枠:5年まで
|
5年まで
|
|
再発の累積発生率(CIR)
時間枠:5年まで
|
5年まで
|
|
造血幹細胞移植(HSCT)率
時間枠:5年まで
|
5年まで
|
|
有害事象(AE)のある参加者の数
時間枠:5年まで
|
5年まで
|
|
ベネトクラクスの最大観察血漿濃度 (Cmax)
時間枠:投与前、サイクル1の投与後2、4、6、8、および24時間、8日目および13日目(サイクルは42日); 5日目から21日目までのサイクル2のフォローアップ来院時に1回
|
投与前、サイクル1の投与後2、4、6、8、および24時間、8日目および13日目(サイクルは42日); 5日目から21日目までのサイクル2のフォローアップ来院時に1回
|
|
ベネトクラクスの最大血漿濃度 (Tmax) までの時間
時間枠:投与前、サイクル1の投与後2、4、6、8、および24時間、8日目および13日目(サイクルは42日); 5日目から21日目までのサイクル2のフォローアップ来院時に1回
|
投与前、サイクル1の投与後2、4、6、8、および24時間、8日目および13日目(サイクルは42日); 5日目から21日目までのサイクル2のフォローアップ来院時に1回
|
|
24 時間の投与間隔での血漿濃度-時間曲線下面積 (AUC0-24)
時間枠:投与前、サイクル1の投与後2、4、6、8、および24時間、8日目および13日目(サイクルは42日); 5日目から21日目までのサイクル2のフォローアップ来院時に1回
|
投与前、サイクル1の投与後2、4、6、8、および24時間、8日目および13日目(サイクルは42日); 5日目から21日目までのサイクル2のフォローアップ来院時に1回
|
|
病気関連死亡率
時間枠:最長5年
|
最長5年
|
|
非疾病関連死亡率
時間枠:最長5年
|
最長5年
|
|
小児微小残存病変(Ped-MRD)陰性で完全寛解(CR)、部分完全寛解(CRp)、または完全寛解かつ血液学的不完全回復(CRi)を有する参加者の数
時間枠:最長5年
|
最長5年
|
|
国際作業部会が完全対応(IWG-CR)した参加者の数
時間枠:最長5年
|
最長5年
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Seth Karol, MD、St. Jude Children's Research Hospital
出版物と役立つリンク
一般刊行物
- Badawi M, Gopalakrishnan S, Engelhardt B, Palenski T, Karol SE, Rubnitz JE, Menon R, Salem AH. Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Clin Ther. 2024 Oct;46(10):759-767. doi: 10.1016/j.clinthera.2024.09.008. Epub 2024 Oct 5.
- Daniels KP, Pounds SB, Wu H, Wang L, Alexander TB, Budhraja A, Wolf J, Westover T, Mead PE, Mehr CM, Gupta SD, Lacayo NJ, Inaba H, Rees M, Pui CH, Opferman JT, Klco JM, Rubnitz JE, Karol SE. Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study. Lancet Haematol. 2026 Aug;13(8):e545-e554. doi: 10.1016/S2352-3026(26)00136-5. Epub 2026 Jul 8.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 組織型別の新生物
- 血液疾患
- 白血病、骨髄性
- 白血病
- ヘミックおよびリンパ疾患
- 白血病、骨髄性、急性
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 核酸、ヌクレオチド、およびヌクレオシド
- 炭水化物
- グリコシド
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- AZA化合物
- ヌクレオシド
- リボヌクレオシド
- アラビノヌクレオシド
- アミノグリコシド
- カリチアミシン
- ゲムツズマブ
- シタラビン
- アザシチジン
- フルダラビン
- ベネトクラックス
その他の研究ID番号
- ITCC-101/APAL2020D
- 2021-003212-11 (EudraCT番号)
- 2023-510160-12-00 (Ctis)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。